Hainan Boao Lecheng International Medical Tourism Pilot Zone holds event to attract Japanese investment
PR91872
BOAO, China, Sept. 23, 2021 /PRNewswire=KYODO JBN/ --
- The event is co-organized by Winhealth Pharma
The Hainan Boao Lecheng International Medical Tourism Pilot Zone ("Lecheng
Pilot Zone")'s virtual promotional event to explain the favorable investment
policies put in place for Japanese businesses, hosted by the administration of
the Hainan Boao Lecheng International Medical Tourism Pilot Zone ("Lecheng
Administration") and co-organized by Hong Kong Winhealth Pharma Group
("Winhealth Pharma"), Boao Winhealth Rare Disease Medical Center ("Rare Disease
Center") and EPS International Holding Co., Ltd. (EPSI), was held in Boao,
China on September 16, 2021.
Lecheng Administration director Gu Gang said, "As a medical park open to
working with companies and organizations outside of China, Lecheng values the
investments from Japanese pharmaceutical manufacturers. Lecheng is committed to
helping these firms using the pilot zone as a jumping off point from which to
promote and commercialize their innovative products in China, giving patients
across the country an opportunity to benefit from new and efficient medical
technologies from Japan."
According to Hainan Provincial Food and Drug Administration deputy director Li
Yunda, 5,380 patients have to date received treatment that was provided by 173
categories of drugs and medical devices imported in response to the urgent
clinical needs since the State Council granted the People's Government of
Hainan Province rights to approve the import of this range of products in 2018.
Lecheng Administration deputy director Lv Xiaolei explained that according to
the Opinions on Supporting the Hainan Free Trade Port in Implementing Certain
Special Measures for Improving Market Access, Lecheng Pilot Zone was provided
with an opportunity to test new favorable policies used to streamline the
approval process. With the support of the Hainan Provincial Health Commission,
Hainan Provincial Food and Drug Administration and Haikou Customs, the approval
time for imported medical devices will be reduced from 27 days on average to
3-7 days.
Hainan Real World Data Research Institute executive director Chen Pingyan
pointed out that high-quality data, good design, and accurate analysis and
result interpretation play a key role in the process of converting real-world
data to evidence. Chen Pingyan also shared an example of the successful rollout
of licensed medical devices in China through Lecheng's Real World Study (RWS)
program. He said the RWS program will facilitate the launch of drugs by making
full use of the opportunity to test revolutionary measures meant to help
international pharmaceutical firms register and market their products in China.
Hong Kong Winhealth Pharma Group vice president Xiao Li said, "With the support
of Lecheng Pilot Zone, the Rare Disease Center has rolled out 31 medical
devices for the treatment of rare diseases since its establishment. The center
is committed to providing Chinese patients with the world's most advanced
solutions for rare disease treatment by collaborating with partners worldwide.
In addition, the center plans to leverage the pilot zone's RWS program to
accelerate the approval for rare disease-related devices that have been
accepted into other markets in a move to benefit Chinese patients afflicted
with such diseases.
With the increasing openness of the Lecheng Pilot Zone, the group plans to
continue promoting and deepening the long-term partnerships between Lecheng and
Japanese businesses by capitalizing on the Rare Disease Center's decision to
bring in Japanese medical devices in a move to provide Chinese patients with an
access to innovative medical solutions from Japan.
SOURCE: HK Winhealth Pharma Group
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。